PARIS--(BUSINESS WIRE)--AAVLife SAS, a company developing gene-therapy products, today announces the grant of a key United States patent for a therapy under development at AAVLife for the treatment of ...

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Friedreich's Ataxia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...

PARIS--(BUSINESS WIRE)--AAVLife, a gene-therapy company focusing on rare diseases, today announced that it has raised $12 million in Series A financing to advance into clinical studies the promising ...

Solid Biosciences announces FDA clearance for SGT-212, targeting Friedreich’s ataxia with dual gene therapy administration routes, initiating Phase 1b trial in 2025. Solid Biosciences Inc. announced ...

THOUSAND OAKS, Calif., Nov. 12, 2024 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced new preclinical data for CAP-004, a potential best-in-class systemically administered ...

Solid Biosciences' SGT-212, dual-route gene therapy for Friedreich’s ataxia, receives FDA Fast Track designation for expedited development. Solid Biosciences Inc. has announced that its gene therapy ...

The transfer, via a viral vector, of a normal copy of the gene deficient in patients, allowed to fully and very rapidly cure the heart disease in mice. These findings are published in Nature Medicine ...

A health care provider outlines treatment objectives and supportive interventions for managing Friedreich ataxia, addressing associated comorbidities and symptoms in clinical settings. August 7th ...

Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that it has received Fast Track designation from the US Food ...

In mice, the transfer via a viral vector of a normal copy of the gene deficient in patients, allowed to fully and very rapidly cure the heart disease. These findings are published in Nature Medicine ...

NHP data demonstrate potential for CAP-004 to treat CNS, cardiac, and sensory manifestations of Friedreich's ataxia THOUSAND OAKS, Calif., Nov. 12, 2024 /PRNewswire/ -- Capsida Biotherapeutics ...

Gene therapy was successfully used to overcome the cardiac effects of Freidreich’s ataxia (FA) in a mouse model of the disease, as reported in the peer-reviewed journal Human Gene Therapy. Click here ...